PMID- 33047221
OWN - NLM
STAT- MEDLINE
DCOM- 20211110
LR  - 20211110
IS  - 1178-1661 (Electronic)
IS  - 1178-1653 (Linking)
VI  - 14
IP  - 1
DP  - 2021 Jan
TI  - Generating Relevant Information from Patients in the Technology-Enhanced Era of 
      Patient-Focused Drug Development: Opportunities and Challenges.
PG  - 11-16
LID - 10.1007/s40271-020-00455-2 [doi]
AB  - The era of patient-focused drug development (PFDD) brings with it a greater use 
      of patient-reported outcome measures (PROMs) in clinical trials. This is 
      facilitated through electronic technology designed to capture PROM data. However, 
      PFDD goes beyond just PROMs, and technology has a key role in capturing timely 
      and patient-relevant information through active and passive means to inform study 
      endpoints. This brief paper aims to highlight four trends the authors have 
      observed across the pharmaceutical industry in using technology to enhance PFDD: 
      (1) capturing qualitative data from patients; (2) using digital health technology 
      tools (DHTTs); (3) employing reactive technology-enabled clinical outcome 
      assessments TeCOA; and (4) generating passive patient experience data. 
      Opportunities and challenges associated with these trends are discussed, and a 
      'call to action' is made to consolidate learning and understanding across 
      science, medical and technology disciplines, and to conduct collaborative 
      research to improve the opportunities and minimize the challenges.
FAU - Reaney, Matthew
AU  - Reaney M
AUID- ORCID: 0000-0003-2918-722X
AD  - IQVIA, 3 Forbury Place, 23 Forbury Road, Reading, RG1 2JH, UK. 
      matthew.reaney@iqvia.com.
FAU - Cline, Jennifer
AU  - Cline J
AD  - IQVIA, Pittsburgh, USA.
FAU - Wilson, James C
AU  - Wilson JC
AD  - IQVIA, Philadelphia, USA.
FAU - Posey, Michael
AU  - Posey M
AD  - IQVIA, Pittsburgh, USA.
LA  - eng
PT  - Journal Article
DEP - 20201013
PL  - New Zealand
TA  - Patient
JT  - The patient
JID - 101309314
RN  - 0 (Pharmaceutical Preparations)
SB  - IM
MH  - *Drug Development
MH  - Drug Industry
MH  - Humans
MH  - *Patient Reported Outcome Measures
MH  - *Pharmaceutical Preparations
MH  - Technology
EDAT- 2020/10/14 06:00
MHDA- 2021/11/11 06:00
CRDT- 2020/10/13 05:40
PHST- 2020/09/08 00:00 [accepted]
PHST- 2020/10/14 06:00 [pubmed]
PHST- 2021/11/11 06:00 [medline]
PHST- 2020/10/13 05:40 [entrez]
AID - 10.1007/s40271-020-00455-2 [pii]
AID - 10.1007/s40271-020-00455-2 [doi]
PST - ppublish
SO  - Patient. 2021 Jan;14(1):11-16. doi: 10.1007/s40271-020-00455-2. Epub 2020 Oct 13.